Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an announcement.
Chimeric Therapeutics Limited has confirmed that shareholders approved a consolidation of its capital structure at a general meeting held on 17 April 2026. The move affects the company’s ordinary fully paid shares, various listed options, and performance rights, and it updates an earlier announcement made on 19 March 2026.
The security consolidation is intended to reorganise the company’s quoted securities on the ASX, potentially simplifying its capital base and improving the structure of its listed instruments. This change may impact how investors assess the company’s share price, liquidity, and future capital management as the consolidation takes effect across all affected securities.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is an ASX-listed biotechnology company focused on developing innovative therapies, including options and performance rights tied to its ordinary fully paid shares. The company operates in the life sciences sector, using capital market securities to support its research, development, and commercialisation activities in therapeutics.
Technical Sentiment Signal: Sell
Current Market Cap: A$6.63M
Learn more about CHM stock on TipRanks’ Stock Analysis page.